Skip to main content
Clinical Trials/EUCTR2017-003779-75-ES
EUCTR2017-003779-75-ES
Active, not recruiting
Phase 1

Randomized clinical trial to assess the impact of treatment with empagliflozine on systemic inflammatory and renal parameters in patients with Diabetes Mellitus type 2 and ischemic heart disease.

Hospital Universitario La Paz0 sites80 target enrollmentOctober 13, 2017

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Type 2 Diabetes Mellitus
Sponsor
Hospital Universitario La Paz
Enrollment
80
Status
Active, not recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 13, 2017
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients diagnosed with type 2 DM with poor metabolic control (glycosylated hemoglobin\> 6\.5%)
  • 2\. Patients who have suffered an acute myocardial infarction or who have undergone a coronary revascularization procedure within 30 days prior to the start of the study.
  • 3\. Over 18 and under 85
  • 4\. Treatment with any hypoglycaemia including insulin.
  • 5\. Left ventricular ejection fraction preserved (LVEF\> 40%)
  • 6\. Patients who have signed their consent to participate in the study
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 60

Exclusion Criteria

  • 1\. Patients with type 1 DM.
  • 2\. Previous or current treatment with an SGLT2 inhibitor.
  • 3\. Creatinine clearance \<60 ml / min / 1\.73m2\.

Outcomes

Primary Outcomes

Not specified

Similar Trials